Receptor Tyrosine Kinase Inhibitor Nintedanib as Treatment Option in Bronchiolitis Obliterans after Airway Transplantation

The major obstacle for long-term survival after successful lung transplantation is the development of chronic lung allograft dysfunction (CLAD). It has been shown that nintedanib, an intracellular inhibitor of receptor tyrosine kinases, has a beneficial effect in the treatment of neoplastic diseases and idiopathic pulmonary fibrosis. Nintedanib influences three major angiogenic signalling pathways by blocking the receptors for: platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF).

Source: The Journal of Heart and Lung Transplantation - March 16, 2019 Category: Transplant Surgery Authors: C. Heim, J. Mauer, A. Kuckhahn, J. Distler, B. Spriewald, M. Ramsperger-Gleixner, M. Weyand, S.M. Ensminger Tags: 321 Source Type: research